Today's Healthcare Pulse

FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing

Education Creates Inroads for Concurrent Pediatric Care
At the ELEVATE conference, hospice leaders highlighted that many clinicians still lack awareness of concurrent hospice and palliative care for seriously ill children, a model that allows curative treatment to continue alongside hospice services. They argued that targeted education and clearer billing guidance could expand referral networks and create sustainable reimbursement pathways. Research links increased use of concurrent care to fewer aggressive interventions and lower end‑of‑life expenses. Stakeholders called for better training and policy clarification to unlock these benefits for underserved pediatric populations.
How Computer Vision Fits Into a Smart Hospital Room
Artisight’s Chief Nursing Officer Karie Ryan outlined the company’s ambient intelligence platform that fuses audio, video, sensor data and computer‑vision algorithms into a single smart hospital room. The solution continuously monitors patients and staff, automatically detecting safety risks such as...
Tortugas Takes Neuro Deep Dive with $106M to Develop Eisai, Hansoh Programs
Tortugas, a Massachusetts‑based biotech, launched with $106 million in seed and Series A funding, securing clinical assets from Japan’s Eisai and China’s Hansoh Pharmaceutical. The capital will support two mid‑stage, oral small‑molecule trials targeting CNS disorders such as schizophrenia, tinnitus, and focal...
NIMBLE Trial Shows Efficacy of Cemdisiran in gMG: Tuan Vu, MD
The phase 3 NIMBLE trial evaluated cemdisiran, an RNA‑interference therapy, in patients with generalized myasthenia gravis (gMG). Over 26 weeks, cemdisiran monotherapy and its combination with pozelimab both achieved statistically significant improvements on the MG‑ADL scale versus placebo, and met the key...
Does Medicaid Expansion Help or Hurt Hospital Finances?
A new CEPR issue brief finds that Medicaid expansion under the ACA has generally bolstered hospital finances. Expansion states saw a roughly 5% drop in uncompensated care costs and a modest rise in insured emergency‑room visits. Most hospitals reported 2‑3%...
Boehringer Targets AI-Driven Advances in Disease Research
Boehringer Ingelheim announced a £150 million (US$203 million) AI and machine‑learning accelerator in King’s Cross, London, expanding its global computational R&D network. The new hub, part of the UK Knowledge Quarter, will focus on disease biology, target identification and predictive modeling to...
Silence in Health Care Still Kills: Communication Failures Continue to Threaten Patients and Health Care Innovation
A new national survey of 3,500 clinicians and administrators, dubbed "Silence Kills 2.0," reveals that while speaking up has risen to 32% of respondents, a majority still remain silent about unsafe practices. The study finds 40% of staff witness rule violations...

Robotic Cataract Surgery Opens Path for Millions
this is so exciting to see a robot just performed the first complete cataract surgery on a human patient, with no surgeon's hands on the tools and no general anesthesia cataract surgery is where the eye's clouded lens gets swapped for an...

BioAge Reports Positive Phase 1 Data for BGE-102
BioAge Labs announced Phase 1 results for BGE‑102, an oral, brain‑penetrant NLRP3 inhibitor, showing up to 86% reductions in high‑sensitivity C‑reactive protein (hsCRP) in obese participants. A 60 mg once‑daily regimen over 21 days achieved biomarker improvements comparable to the previously tested...
[Comment] Is Partial Complement Blockade Enough in Myasthenia Gravis?
The past eight years have seen a rapid expansion of targeted therapies for generalized myasthenia gravis, including complement C5 inhibitors, neonatal Fc receptor antagonists, and the anti‑CD19 B‑cell‑depleting antibody inebilizumab. Clinical trials have demonstrated meaningful reductions in disease activity, prompting...

I Wear a Continuous Glucose Monitor. Here's What MOTS-C Did to My Numbers.
The author, a biohacker who monitors glucose continuously, reports that weekly injections of the mitochondrial peptide MOTS‑c consistently drop post‑meal blood sugar by about 20 mg/dL compared with baseline. The effect appears reproducible across multiple CGM recordings while keeping food intake...

Randomization Inside a Medicare Payment Model, It's Really Cool
The CMS Innovation Center’s ACCESS Model launches a ten‑year, national test of outcome‑aligned payments for technology‑enabled chronic care, offering fixed payments of $90 to $420 per beneficiary across four disease tracks. A distinctive feature is the 90:10 randomization of eligible...
GLP‑1 Therapy Halves Insulin Use in Type 1 Diabetes
I so don't want to add to The Discourse, but I do have to say that the use of a GLP-1 has been a miracle for my Type 1 diabetes (not even the kind that the drugs are made for)....
Distinguish Dilutional Vs. Iron‑Deficiency Anemia in Pregnancy
Almost every pregnant woman's blood work shows anemia at some point. But there are two very different reasons for it and most providers do not distinguish between them. The first is dilutional. Your plasma volume increases by about 50% during pregnancy...

Our Friends in the Lab: A Lab Week Tribute
The post celebrates Medical Laboratory Professionals Week (April 19‑25) by highlighting two young lab technologists, Ayla and Hayley, who demonstrated cutting‑edge automation and meticulous neonatal blood‑type workups. Ayla explained how automated microbiology systems and digital plate reading are reshaping pathogen...
AI Could Turn $30B Healthcare Data Into Value
We spent $30 billion digitizing American healthcare. It got used for billing. New Lifers episode with @Farzad_MD, physician, former National Coordinator for Health IT, and CEO of @AledadeACO, on what went wrong, and why AI might finally fix the incentives, with...
Promising Mufemilast Results Unveiled at DDW
Strong mufemilast data being presented at DDW this week for anyone still following the $PALI story. https://t.co/Oi4WI6R0iW

Alesi Surgical Raises £7M to Clear the Air in Operating Theatres with Next-Gen Smoke Management Tech
Alesi Surgical announced a £7 million ($9 million) funding round led by IW Capital to accelerate its Ultravision smoke‑management platform. The technology uses electrostatic precipitation to clear surgical smoke up to 225‑times faster than conventional suction, already deployed in over 50,000 minimally...
CMS Threatens States with Audits and Federal Scrutiny
CMS will ask states for new health provider audits, Oz says. If states don't take it 'seriously,' they could become targets of further federal scrutiny. https://t.co/IIBNZ8oWrM

AI Misses Primary Diagnosis Over 80% of Time
AI fails at primary patient diagnosis more than 80% of the time, study finds 🔗https://t.co/EauFgd4tJC 🌐 #DHPSP #DigitalHealth https://t.co/VjsiqaFfkS
Blue Shield of California Taps Chief Pharmacy Officer
Blue Shield of California has appointed Hayley Park as senior vice president and chief pharmacy officer. Park, formerly vice president of pharmacy operations at Kaiser Permanente Northern California, will oversee the insurer’s prescription‑drug programs and the Pharmacy Care Reimagined initiative....

Pesticide Exposure Correlates with Early‑Onset Colorectal Cancer
Why are we seeing so much early-onset colorectal cancer? The correlation with pesticide exposure and its epigenetic signature, adjusted for all known risk factors. (doesn't establish cause and effect) https://t.co/1UiBiHkgo5
AI Accelerates Small Molecule Synthesis, Says Martin Burke
Small molecule synthesis made faster for the AI era: Listen to Martin Burke on The Long Run. Sponsors: @AlphaSenseInc and Dash Bio. https://t.co/D990phgzg8

The Next Era of Payment Integrity: Earlier Clinical Validation, True Transparency
Health plans are moving payment integrity left by applying clinical and coding validation before claims are paid. The industry faces over $200 billion in annual waste and abuse, and legacy post‑pay processes consume a third of integrity resources. Leveraging domain‑specific AI...
UK Bans Cigarettes for Under‑30s, Targeting Smoke‑free Generation
JUST IN: UK bans cigarette sales for anyone born after Jan 1, 2009, aiming to create a “smoke-free generation”

BHN Spring 2026 Issue
The Spring 2026 issue of Behavioral Health News spotlights the expanding role of peer services across the behavioral health continuum. It features a collection of articles that examine peer integration in crisis response, outpatient programs, workplace mental health, and state‑level...
APOE Ε4 Predicts Early Cognitive Decline in Midlife Adults
APOE ε4 and Accelerated Cognitive Decline Among Cognitively Healthy Middle-Aged and Older Adults 🗣️” In this study, APOE ε4 carrier status was associated with early cognitive decline, highlighting midlife risk awareness and lifestyle interventions, while non-APOE polygenic risk may require longer...
Rare Measles Complication Kills Child Years After Infection
Subacute sclerosing panencephalitis is a rare but fatal side effect of #measles infection, which manifests years after a kid recovers. This story of a family who lost a 10-year old to it is heartbreaking. Renae was too young to be...
Re: Alzheimer’s Drugs Targeting Amyloid Do Not Produce Clinically Meaningful Effects, Concludes Cochrane Review
A recent Cochrane review concluded that amyloid‑targeting drugs for Alzheimer’s disease do not deliver clinically meaningful benefits, prompting disappointment among researchers, investors, and caregivers. In a BMJ rapid response, emeritus professors Elaine and Robert Perry argue that cholinergic therapy—available for...
Dayton Children’s Whitlock Says TEFCA Trust Model Needs Stronger Guardrails to Stop Data Misuse
In this episode, Dayton Children’s CIO J.D. Whitlock discusses the challenges of TEFCA’s trust model, highlighting how inadequate guardrails have allowed patient data to be misused for non‑clinical purposes, exemplified by the Health Gorilla lawsuit. He explains the complex governance...

STAT+: Pharmalittle: We’re Reading About a Purdue Pharma Settlement, a Setback for Merck and Eisai, and More
Pfizer executive Andrew Baum, a former Citibank analyst who joined in June 2024, has left his EVP and chief strategy role but will stay on as an adviser to CEO Albert Bourla through the end of the year. His departure...

Sun Pharma’s ‘Heart Ke Liye 8’ Campaign Crosses 24.1 Million Views
Sun Pharmaceutical Industries’ "Heart ke Liye 8 – Making India Heart Strong" campaign has amassed 24.1 million views since its February launch, leveraging YouTube, Meta, connected TV and health‑tech platforms to promote eight daily habits for cardiovascular wellness. The initiative dovetails...
Merck, Eisai’s Keytruda Triplet Fails to Improve Survival in Kidney Cancer
Merck and Eisai announced that their Phase 3 LITESPARK‑012 trial of a three‑drug regimen—Keytruda, Welireg and Lenvima—failed to improve overall survival or progression‑free survival in first‑line renal cell carcinoma. The control arm received the approved Keytruda‑Lenvima doublet, which also did not...

Black Doulas, Maternal Health, and the Erasure We've Never Talked About
The episode explores the centuries‑old role of Black doulas and midwives—tracing their roots to West African traditions and their dominance in U.S. births from the 1600s through the early 20th century. It explains how the medicalization of childbirth shifted care...

Revenue Isn’t the Signal: What Early-Stage Health Tech Investors Should Be Watching Instead
Claire Smith of SpringTide Ventures argues that early‑stage health‑tech investors should look beyond headline revenue. She emphasizes customer adoption, sales motion, and scalability within regulated systems as stronger predictors of success. Early contracts may be modest but valuable if they...

SaNOtize - 727784 - 04/17/2026
The U.S. Food and Drug Administration issued a warning letter to SaNOtize, the maker of “NOWONDER™ Nasal Cleanser,” on April 17, 2026. The agency determined the product is an unapproved new drug because its labeling and website claim nitric‑oxide‑based immune benefits, violating sections 505(a)...

Pro Numb Tattoo Numbing Spray, LLC - 722589 - 04/14/2026
The FDA issued a warning letter to Pro Numb Tattoo Numbing Spray, LLC for multiple Current Good Manufacturing Practice (CGMP) violations, including failure to test finished drug batches, inadequate raw‑material verification, and lack of stability data. The firm also marketed...
Mabwell’s T‑mab Subsidiary Clears First‑Time GMP Inspection in Jordan, Boosting Middle‑East Push
Mabwell announced that its subsidiary T‑mab successfully passed a Jordan Food and Drug Administration on‑site GMP inspection, earning a “Compliance” rating for its denosumab biosimilars. The milestone, the company’s first approval from a PIC/S member country, is expected to accelerate...
Eli Lilly to Acquire Kelonia Therapeutics in $7 B Cash Deal
Eli Lilly agreed to acquire Cambridge‑based Kelonia Therapeutics for up to $7 billion in cash, including an undisclosed upfront payment. The deal adds Kelonia’s in‑vivo gene‑delivery platform and its lead candidate KLN‑1010 to Lilly’s oncology portfolio, and sent Lilly’s shares up 2.5%...

IBS News Flash. Anxiety & IBS Have a Reciprocal Relationship
A retrospective cohort study published in Cureus identified a strong two‑way relationship between anxiety and irritable bowel syndrome (IBS). Individuals with anxiety were more likely to develop IBS later, while those with IBS faced more than double the risk of...
EClinicalWorks CEO Charts AI‑Driven Overhaul of EHR Workflows
eClinicalWorks CEO Dr. Rahul Patel announced a comprehensive AI strategy that will embed real‑time intelligence into its electronic health record platform, promising faster decision‑making while safeguarding reliability and patient safety. The plan targets ambulatory practices nationwide and positions the company...
Danielle DeBoer Named SVP of Human Resources at Cosette Pharmaceuticals
Cosette Pharmaceuticals has hired Danielle DeBoer as senior vice president of Human Resources. The veteran HR leader brings experience from private‑equity‑backed firms and global pharma, positioning Cosette to accelerate team growth, M&A integration and DEI initiatives as it expands its...
Chinese Researchers Propose Saliva Test to Detect Stomach Cancer Early
Researchers from Shanghai Jiao Tong University School of Medicine have pinpointed 20 bacterial species that appear in both the mouths and stomachs of gastric‑cancer patients. Their study, published in Cell Reports Medicine, proposes a non‑invasive saliva test that could identify...
BBOT Secures FDA Fast Track for Pan-KRAS Inhibitor BBO-11818 in KRAS‑Mutant Pancreatic Cancer
BridgeBio Oncology Therapeutics (BBOT) announced that the FDA granted Fast Track designation to its pan‑KRAS inhibitor BBO-11818 for advanced KRAS‑mutant pancreatic ductal adenocarcinoma. The designation accelerates development of a drug that showed a confirmed partial response in early data and...

Where Utah’s Experiment with AI Doctors Is Headed Next
Utah has launched a regulatory sandbox that lets AI-driven health platforms prescribe medications under physician oversight, a move that bypasses typical federal restrictions. The state allocated roughly $5 million to attract startups such as Babylon Health and AIMD for pilot programs...

When Shared Decision Making Gives Way to Medical Paternalism
The article highlights how the ideal of shared decision making is increasingly supplanted by medical paternalism, illustrated by a family's struggle to secure a feeding tube for a father with advanced dementia. Physicians sometimes refuse procedures they deem clinically futile,...
NIPT in 2026: How AI and Next-Gen Sequencing Are Changing Prenatal Screening
Non‑invasive prenatal testing (NIPT) in the UK is being reshaped by next‑generation sequencing and artificial‑intelligence algorithms. AI‑driven analysis lifts the positive predictive value for trisomies to roughly 88%, while proprietary enrichment steps like Focus Plus increase fetal DNA fractions 3.6‑fold, slashing...
Neolaia Synthesizes New CD38 Inhibitors
Biohaven disclosed detailed preclinical data on BHV‑2100, a TRPM3 calcium‑channel modulator aimed at neuropathic pain. A new meta‑analysis concluded that anti‑amyloid therapies for Alzheimer’s have not demonstrated clinically meaningful benefits, intensifying debate over the approach. Jiangsu and Shanghai Hengrui patented...

ConcertAI Launches Cadence Suite to Accelerate Patient Access to Life-Changing Therapies
ConcertAI has launched Cadence Suite, an AI-native platform for pharma commercial and field teams to proactively identify and resolve patient access barriers. The suite unifies specialty pharmacy, claims, and social determinants of health data into a single view, enabling real‑time...
Incyte Discloses New TYK2 And/Or JAK1 Inhibitors
Incyte announced the discovery of a new series of small‑molecule inhibitors that selectively target TYK2 and JAK1, two kinases central to cytokine signaling in autoimmune disorders. The compounds demonstrated sub‑nanomolar potency in cell‑based assays and favorable safety margins in early...